Progyny (PGNY) PT Lowered to $21 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PGNY Hot Sheet
Price: $29.06 --0%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst Richard Close lowered the price target on Progyny (NASDAQ: PGNY) to $21.00 (from $23.00) while maintaining a Hold rating.
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $340 at BMO Capital
- Covista (CVSA) PT Raised to $146 at BMO Capital
- Coca-Cola Europacific Partners (CCEP) PT Raised to $110 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
